Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BIO-TECHNE (TECH) Shares Outstanding (Diluted Average): 2009-2021

Historic Shares Outstanding (Diluted Average) for BIO-TECHNE (TECH) over the last 6 years, with Dec 2021 value amounting to $41.2 million.

  • BIO-TECHNE's Shares Outstanding (Diluted Average) rose 2.36% to $41.2 million in Q4 2021 from the same period last year, while for Dec 2021 it was $41.2 million, marking a year-over-year increase of 2.36%. This contributed to the annual value of $40.5 million for FY2021, which is 2.75% up from last year.
  • Per BIO-TECHNE's latest filing, its Shares Outstanding (Diluted Average) stood at $41.2 million for Q4 2021, which was up 0.12% from $41.2 million recorded in Q3 2021.
  • In the past 5 years, BIO-TECHNE's Shares Outstanding (Diluted Average) ranged from a high of $41.2 million in Q4 2021 and a low of $37.5 million during Q2 2017.
  • Over the past 3 years, BIO-TECHNE's median Shares Outstanding (Diluted Average) value was $39.8 million (recorded in 2019), while the average stood at $39.9 million.
  • Data for BIO-TECHNE's Shares Outstanding (Diluted Average) shows a peak YoY rose of 3.15% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows BIO-TECHNE's Shares Outstanding (Diluted Average) stood at $37.9 million in 2017, then grew by 2.17% to $38.7 million in 2018, then rose by 2.07% to $39.5 million in 2019, then increased by 1.79% to $40.3 million in 2020, then rose by 2.36% to $41.2 million in 2021.
  • Its last three reported values are $41.2 million in Q4 2021, $41.2 million for Q3 2021, and $40.5 million during Q2 2021.